网站首页期刊介绍通知公告编 委 会投稿须知电子期刊广告合作联系我们
最新消息:
参芎葡萄糖注射液结合三维适形外照射放射治疗Ⅲ期老年非小细胞肺癌临床疗效观察
作者:贡海  
单位:济南军区总医院放疗科
关键词:参芎葡萄糖注射液 三维适形外照射放射治疗 老年 Ⅲ期非小细胞肺癌 
分类号:
出版年·卷·期(页码):2010·38·第六期(580-584)
摘要:

[摘 要] 目的:观察参芎葡萄糖注射液结合三维适形外照射放射治疗Ⅲ期老年非小细胞肺癌临床疗效和放射治疗的毒副反应,对中西医结合治疗非小细胞肺癌进行可行性探讨。方法:65例Ⅲ期老年非小细胞肺癌患者随机分成两组,应用参芎葡萄糖注射液分为A 组,32例,:直线加速器6MV的X射线,进行纵隔区及原发病灶的三维适形外照射放疗,200cGy次/日,5次/周,总剂量4000cGy。原发病灶三维适形放射治疗追加剂量放疗,200cGy/日,1次/日,共10次,总剂量2000cGy。放疗开始当天参芎葡萄糖注射液100ml静脉注射,1次/日,共6周。B组:33例,放射治疗方法同A组,放疗当天开始生理盐水250ml加入维生素C注射液2g、维生素B6注射液200mg静脉滴注,1次/日,共6周。观察两组术后肿瘤近期疗效、生存率(术后3、6、12、18个月生存率)、免疫功能、放疗后生存质量和毒副反应。结果:A组治疗后,A组有效率:(CR+PR)为71.9%,B组为45.5% (P<0.05),两组CR分别为46.7%、24.2%(P<0.05)。表明A组的有效率、CR率与B组有明显差异。A组3、6、12、18个月生存率分别为96.88 % 、90.63%、71.9%、34.4%,平均生存期为16.2±3.1月;B组患者术后3、6、12、24个月生存率分别为93.94%、72.73%、60.6%、27.3%,平均生存期为13±2.3月,两组比较12月、18月生存率无显著差异(P值>0.05)。A组近期疗效与B组比较明显优于对照组。免疫功能、放疗后生存质量A组明显好于B组,A组毒副反应明显较B组减轻。结论:参芎葡萄糖注射液结合三维适形外照射放射治疗Ⅲ期非小细胞肺癌,可明显改善老年患者的生存质量,减轻放射治疗的毒副反应。

[Abstract] Objective To observe the local control rate and serious toxicity on the 3-dimensional conformal radiation therapy in elderly patients with Ⅲ non-small cell lung cancer. Method : 65cases with NSCLC elderly patients were randomly divided into two groups: A group and B group. A group included 32cases treated with senate ligusticum glucose injection on the 3-dimensional conformal radiation therapy, B group included 33 cases with vitC and vitB6 injection. To observe the clinical characteristic of tumor, recent effects, toxication and side effects and survival condition(postoperative survival rate in 3,6,12 and 18month, respectively). Results The CR rate of group A is higher than that of group B(p<0.05). Postoperative survival rate of A group were 96.88 % 、90.63%、71.9% and 34.4%in 3,6,12,and18month;B group were 93.94 % 、72.73%、60.6% and 27.3%in 3,6,12,and18month respectively, no significant difference from that of B group. The side effects and toxications of A groups was better than B group. Conclusion Senate ligusticum glucose injection on the 3-dimensioconformal radiation therapy in elderly patients with Ⅲ non-small cell lung cancer could reduced the side effects and toxications of tumor, significant difference between the two groups .

参考文献:
服务与反馈:
文章下载】【发表评论】【查看评论】【加入收藏
提示:您还未登录,请登录!点此登录
您是第 753202 位访问者


 ©《现代医学》编辑部
联系电话:025-83272481;83272479
电子邮件: xdyx@pub.seu.edu.cn

苏ICP备09058541